Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 280

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)

Paul, C., Lacour, J.‐P., Tedremets, L., Kreutzer, K., Jazayeri, S., Adams, S., Guindon, C., You, R., Papavassilis, C., the JUNCTURE study group·2015·Journal of the European Academy of Dermatology and Venereology

Abstract

Background: Secukinumab is a fully human anti–interleukin‐17A monoclonal antibody. Objective: Determine the efficacy, safety and usability of secukinumab administered via autoinjector/pen. Methods: This phase III trial randomized subjects with moderate to severe plaque psoriasis to secukinumab 300 mg, 150 mg or placebo self‐injection once weekly to Week 4, then every 4 weeks. Co‐primary end points at Week 12 were ≥75% improvement in Psoriasis Area and Severity Index (PASI 75) and clear/almost clear skin by investigator's global assessment 2011 modified version (IGA mod 2011 0/1). Secondary end points included autoinjector usability, assessed by successful, hazard‐free self‐injection and subject‐reported acceptability on Self‐Injection Assessment Questionnaire. Results: Week 12 PASI 75 and IGA mod 2011 0/1 responses were superior with secukinumab 300 mg (86.7% and 73.3%, respectively) and 150 mg (71.7% and 53.3%, respectively) vs. placebo (3.3% and 0%, respectively) (P < 0.0001 for all). All subjects successfully self‐administered treatment at Week 1, without critical use‐related hazards. Subject acceptability of autoinjector was high throughout 12 weeks. Adverse events were higher with secukinumab (300 mg, 70.0%; 150 mg, 63.9%) vs. placebo (54.1%), with differences largely driven by mild/moderate nasopharyngitis. Conclusion: Secukinumab delivered by autoinjector/pen is efficacious, well‐tolerated and associated with high usability in moderate to severe plaque psoriasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdv.12751

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 280

Metadata

Authors
Paul, C., Lacour, J. ‐., Tedremets, L., Kreutzer, K., Jazayeri, S., Adams, S., Guindon, C., You, R., Papavassilis, C., & the JUNCTURE study group
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2014-09-22
Volume
29
Issue
6
Pages
1082-1090
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W2103750969
Cited by
280
References
21
FWCI
11.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). https://app.cochat.ai/papers/10.1111/jdv.12751
The paper
Paul, C., Lacour, J. ‐., Tedremets, L., Kreutzer, K., Jazayeri, S., Adams, S., Guindon, C., You, R., Papavassilis, C., & the JUNCTURE study group. (2015). Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.12751

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.